Back to all assets

GE HealthCare GEHC

equity

Price History

$58.38$70.2$82.03$93.85
2022-12 · DCA start$58.38

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-35.2%-23.4%-11.7%0.0%
2022-122026-08 · -23.0%

Worst drawdown: −35%, peaking Sep 2024 and bottoming Apr 2026 — still unrecovered after 23 months.

DCA Backtest

Invested
$4,500
Value today
$4,296
Return
-4.5%
Months invested
45

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $4,739 today, so the real (inflation-adjusted) return is -9.3%.

Lump sum instead — $4,500 all at once in Dec 2022: $5,571 (+23.8%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Sep 2024): $2,299 on $2,400 invested (-4.2%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2022-12: -4.5%

About GE HealthCare

GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures contrast agents and radiopharmaceuticals. (Wikipedia)

It's a listed company categorised under health care and health care equipment, with a market cap of about $32.6B.

It rates Medium-High Risk at 2.3/5, meaning real but ordinary risk — the kind most mainstream assets carry, with some factors scoring poorly.

What pushes the score up: earnings quality (3.0/5) and sector / regulatory (3.0/5).

Scoring well: liquidity at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-High Risk(2.3/5)80% rated

How these ratings work

Market / Volatility2.3/5 · weight 20%
  • Annualised volatility (3yr)3/529.0
  • Max drawdown from ATH2/535.2
  • Beta vs S&P 5002/50.84
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5360.4m
  • Float % of shares outstandingnot yet researched
Leverage / Financial2.5/5 · weight 20%
  • Debt / equity3/50.92
  • Interest coverage (EBIT / interest)2/56.3
Earnings Quality3.0/5 · weight 15%
  • 3yr EPS volatility3/527.1
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.